Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Setrusumab

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ultragenyx & Mereo BioPharma Announce New Pha2 Data from Phase 2/3 Orbit Study
    Ultragenyx & Mereo BioPharma Announce New Pha2 Data from Phase 2/3 Orbit Study

    11 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/11/2897217/20739/en/Ultragenyx-and-Mereo-BioPharma-Announce-New-Phase-2-Data-from-Phase-2-3-Orbit-Study-Demonstrating-Sustained-Reductions-in-Fracture-Rates-Following-Treatment-with-Setrusumab-UX143-i.html

    GLOBENEWSWIRE
    11 Jun 2024
    Share Share
    Ultragenyx Completes Enrollment in Ph3 Setrusumab OI Studies ORBIT, COSMIC
    Ultragenyx Completes Enrollment in Ph3 Setrusumab OI Studies ORBIT, COSMIC

    30 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/30/2872207/20739/en/Ultragenyx-Announces-Completion-of-Enrollment-in-Phase-3-Orbit-and-Cosmic-Studies-Evaluating-Setrusumab-UX143-for-the-Treatment-of-Osteogenesis-Imperfecta-OI.html

    GLOBENEWSWIRE
    30 Apr 2024
    Share Share
    Mereo BioPharma Reports Full Year 2023 Financial Results
    Mereo BioPharma Reports Full Year 2023 Financial Results

    27 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/27/2853597/0/en/Mereo-BioPharma-Reports-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share
    Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023
    Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023

    09 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/09/2756624/20739/en/Ultragenyx-to-Present-Setrusumab-UX143-Update-at-ASBMR-2023-Including-New-Data-from-Phase-2-3-Orbit-Study-in-Osteogenesis-Imperfecta-OI.html

    GLOBENEWSWIRE
    09 Oct 2023
    Share Share
    Ultragenyx Announces First Patients Dosed in Ph3 Program Evaluating Setrusumab
    Ultragenyx Announces First Patients Dosed in Ph3 Program Evaluating Setrusumab

    06 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/06/2700255/20739/en/Ultragenyx-Announces-First-Patients-Dosed-in-Phase-3-Program-Evaluating-Setrusumab-UX143-for-the-Treatment-of-Osteogenesis-Imperfecta-OI.html

    GLOBENEWSWIRE
    06 Jul 2023
    Share Share
    Ultragenyx & Mereo Announce Positive Data from Ph2/3 Orbit Study of Setrusumab
    Ultragenyx & Mereo Announce Positive Data from Ph2/3 Orbit Study of Setrusumab

    05 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/05/2682355/20739/en/Ultragenyx-and-Mereo-BioPharma-Announce-Positive-Data-from-the-Ongoing-Phase-2-3-Orbit-Study-of-Setrusumab-UX143-in-Osteogenesis-Imperfecta-OI.html

    GLOBENEWSWIRE
    05 Jun 2023
    Share Share